跳至主要内容
临床试验/NCT04176211
NCT04176211已完成不适用

The Impact of Myasthenia Gravis in the Real World

Vitaccess Ltd1 个研究点 分布在 1 个国家目标入组 2,847 人开始时间: 2019年12月12日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
2,847
试验地点
1
主要终点
Change in Myasthenia Gravis Quality of Life 15-item revised scale (MG-QoL15r) score

研究概览

简要总结

An international, non-interventional, prospective, community recruited, longitudinal, lifestyle study which aims to collect Real-World Evidence (RWE) from people living with myasthenia gravis (MG) in order to map the disease's natural history, its burden on patients and their families, its treatment, as well as its medical, social and pharmacoeconomic impact.

详细描述

Data was collected from people with MG using the MyRealWorld™ RWE platform , developed by the healthcare digital research company, Vitaccess. Participants downloaded a 'bring your own device' (BYOD) study app, MyRealWorld™ MG, onto their smartphones, which they used to enter data and complete surveys about their MG.

研究设计

研究类型
Observational
观察模型
Ecologic Or Community
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adults (aged 18 years and over) with any stage and any subtype of myasthenia gravis disease
  • Resident in Belgium, Canada, France, Germany, Italy, Japan, Spain, the UK, the USA, or Denmark

排除标准

  • No specific exclusion criteria

结局指标

主要结局

Change in Myasthenia Gravis Quality of Life 15-item revised scale (MG-QoL15r) score

时间窗: Once per six months throughout 2 year study duration

The MG-QOL15r is a myasthenia gravis-specific health-related quality of life survey, which assesses the impact of myasthenia gravis over the past few weeks on the following domains: emotions, physical health, self-care, social life, and impact on role. Each of the 15 items has three response options: 0 (Not at all), 1 (Somewhat), and 2 (Very much). The MG-QoL15r total score can be calculated by totalling all 15 items out a maximum score of 30. A higher score indicates severe impairment.

Change in Health Utilities Index III (HUI3) score

时间窗: Once per 12 months throughout 2 year study duration

The HUI3 is a generic 8-item survey, which provides descriptive evidence on multiple dimensions of health status, a score for each dimension of health, and a health-related quality of life score for overall health.Health dimensions include vision, hearing, speech, ambulation/mobility, pain, dexterity, emotion and cognition. Each dimension has five or six response options. It has recall periods of either 'usual health', the past week, two weeks, or four weeks. Scores on individual items are combined to given a combined health state which can then be converted to health utilities. Lower health utilities represent worse health.

Change in EuroQol 5-dimension 5-level (EQ-5D-5L) score

时间窗: Monthly throughout 2 year study duration

The EQ-5D-5L comprises two parts - the EQ-5D-5L descriptive system and the EQ Visual Analogue Scale (EQ VAS). The descriptive system comprises 5 dimensions (mobility, self care, usual activities, pain/discomfort, and anxiety/depression), each with 5 levels (no problems, slight problems, moderate problems, severe problems, and extreme problems - i.e., higher scores represent worse health). The digits for 5 dimensions can be combined in a 5-digit number describing the respondent's health state. The EQ VAS records the respondent's self-rated health on vertical, visual analogue scale with endpoints labelled 'the best health you can imagine' and 'the worst health you can imagine'. Higher scores represent better self-perceived health.

COVID-19 survey results

时间窗: Monthly throughout 2 year study duration

This is a bespoke survey designed to understand the impact of COVID-19 on study participants. It includes questions about whether participants have had COVID, and the consequences if so, whether they have been vaccinated, and how the wider pandemic has affected their MG treatment and quality of life.

Change in Myasthenia Gravis Activities of Daily Living (MG-ADL) score

时间窗: Four times per six months throughout 2 year study duration

The MG-ADL is a myasthenia gravis-specific 8-item scale, which assesses the severity of the following symptoms: talking, chewing, swallowing, breathing, impairment of ability to brush teeth/comb hair, impairment of ability to rise from a chair, double vision, and eyelid droop. Each of the 8 items has 4 response options; 0 (Mild), 1 (Moderate), 2 (Mild) and 3 (Severe). The MG-ADL total score can be calculated by totalling all 8 items out of a maximum score of 24. A higher score indicates severe impairment.

Change in Hospital Anxiety and Depression Scale (HADS) score

时间窗: Once per six months throughout 2 year study duration

The HADS is a frequently used self-rating scale developed to assess psychological distress in non-psychiatric patients. It consists of two subscales, Anxiety and Depression. The instrument comprises 14 items, 7 for the anxiety subscale and 7 for the depression subscale. Each item is scored on a 4-point response scale, scale wording changes for each item with each coding response corresponding with greater impairment or severity. Domain scores can be calculated by totalling all 7 items out of a maximum score of 21. High scores indicate greater severity of that impairment

Change in Single Simple Question (SSQ) and Patient Acceptable Symptom States (PASS) scores

时间窗: Four times per six months throughout 2 year study duration

The SSQ is a single question that asks respondents what percentage of normal they feel with respect to their MG. The PASS is a single question that asks respondents whether they would consider their current disease state to be satisfactory if they had to stay in it for the next few months. The SSQ and PASS will be presented to participants at the same time, as a question pair.

Change in EuroQol 5-dimension 3-level (EQ-5D-3L) score

时间窗: Monthly for three months for participants from the US and Italy only

The EQ-5D-3L is a three-level version of the EQ-5D-5L. It includes the same dimensions as the EQ-5D-5L, but each has only three levels: no problems, some problems, and extreme problems. The EQ VAS is unchanged from the EQ-5D-5L version.

次要结局

  • Change in Patient-Reported Outcomes Measurement Information System (PROMIS) Dyspnea Characteristics score(Once per six months throughout 2 year study duration)
  • Change in Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance short form 6a change(Once per six months throughout 2 year study duration)
  • Change in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue score(Once per six months throughout 2 year study duration)

研究者

发起方
Vitaccess Ltd
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验